All experiments were repeated at least two times, and the number of parallel samples in each experiment was 410
doi: 10.1371/journal.pone.0119034 169 RobinsonA.LubitzI.Atrakchi-BaranesD.Licht-MuravaA.KatselP.LeroithD.et al
Cagrilintide vs tirzepatide (Mounjaro/Zepbound) Mechanism: Cagrilintide: Amylin agonist Tirzepatide: Dual GIP/GLP-1 agonist Both novel approaches Weight loss: Cagrilintide: 10-12% monotherapy Tirzepatide: 15-22% monotherapy Tirzepatide superior as single agent Administration: Both: Weekly subcutaneous injection Both: Similar convenience Side effects: Cagrilintide: Strong GI effects Tirzepatide: Moderate GI effects Similar overall profile Approval status: Cagrilintide: Investigational Tirzepatide: FDA approved Tirzepatide available now Cost (when both available): Likely similar ($1,000-1,500/month) Both premium weight loss options Verdict: Currently, tirzepatide better choice (approved, superior weight loss)
Asimakopoulou, A., Panopoulos, P., Chasapis, C
Use within 90 days of opening to prevent clumping
Many GLP-1 drugs personal injury cases are currently part of an MDL